BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 27496978)

  • 1. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
    Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
    mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.
    Marzi A; Reynolds P; Mercado-Hernandez R; Callison J; Feldmann F; Rosenke R; Thomas T; Scott DP; Hanley PW; Haddock E; Feldmann H
    EBioMedicine; 2019 Nov; 49():223-231. PubMed ID: 31631035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
    Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
    Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
    [No Abstract]   [Full Text] [Related]  

  • 6. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.
    Bushmaker T; Feldmann F; Lovaglio J; Saturday G; Griffin AJ; O'Donnell KL; Strong JE; Sprecher A; Kobinger G; Geisbert TW; Marzi A; Feldmann H
    J Infect Dis; 2023 Nov; 228(Suppl 7):S721-S729. PubMed ID: 37474155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
    Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.
    Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H
    Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
    Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
    PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus-Based Filovirus Vaccines in Nonhuman Primates.
    Marzi A; Feldmann F; O'Donnell KL; Hanley PW; Messaoudi I; Feldmann H
    J Infect Dis; 2023 Nov; 228(Suppl 7):S671-S676. PubMed ID: 37290042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
    Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
    Front Immunol; 2021; 12():703986. PubMed ID: 34484200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
    Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
    Wong G; Qiu X
    Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.
    Lai L; Davey R; Beck A; Xu Y; Suffredini AF; Palmore T; Kabbani S; Rogers S; Kobinger G; Alimonti J; Link CJ; Rubinson L; Ströher U; Wolcott M; Dorman W; Uyeki TM; Feldmann H; Lane HC; Mulligan MJ
    JAMA; 2015 Mar 24-31; 313(12):1249-55. PubMed ID: 25742465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.